These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 20038734

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M.
    J Clin Oncol; 2010 Apr 20; 28(12):2015-23. PubMed ID: 20308671
    [Abstract] [Full Text] [Related]

  • 9. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
    Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L.
    Breast Cancer Res Treat; 2006 Jan 20; 95(1):45-53. PubMed ID: 16267615
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C, Nagumo Y.
    Cancer Chemother Pharmacol; 2008 Mar 20; 61(3):509-14. PubMed ID: 17516068
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
    Osako T, Ito Y, Takahashi S, Tokudome N, Iwase T, Hatake K.
    Cancer Chemother Pharmacol; 2008 Jun 20; 62(1):159-64. PubMed ID: 17882419
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N.
    J Clin Oncol; 2007 Aug 01; 25(22):3246-50. PubMed ID: 17577021
    [Abstract] [Full Text] [Related]

  • 13. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G.
    Lancet Oncol; 2014 Nov 01; 15(12):1351-60. PubMed ID: 25273343
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
    Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S.
    Breast Cancer Res Treat; 2010 Jan 01; 119(1):127-36. PubMed ID: 19690954
    [Abstract] [Full Text] [Related]

  • 15. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA.
    J Clin Oncol; 2013 Mar 20; 31(9):1157-63. PubMed ID: 23382472
    [Abstract] [Full Text] [Related]

  • 16. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG.
    J Clin Oncol; 2007 Sep 01; 25(25):3853-8. PubMed ID: 17679724
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G.
    Onkologie; 2005 Nov 01; 28(11):558-64. PubMed ID: 16249641
    [Abstract] [Full Text] [Related]

  • 18. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
    Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ.
    J Clin Oncol; 2011 Jan 10; 29(2):149-56. PubMed ID: 21115860
    [Abstract] [Full Text] [Related]

  • 19. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
    Glück S, Ross JS, Royce M, McKenna EF, Perou CM, Avisar E, Wu L.
    Breast Cancer Res Treat; 2012 Apr 10; 132(3):781-91. PubMed ID: 21373875
    [Abstract] [Full Text] [Related]

  • 20. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG, Melnik MK, Piette F, Geyer CE, Mamounas EP, Wolmark N.
    Clin Breast Cancer; 2011 Aug 10; 11(4):228-34. PubMed ID: 21684812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.